TNGX Tango Therapeuticsdata gap · 52% coveragelimited data
Health Care · Pharmaceutical Preparations · close $22.04 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Tango Therapeutics (TNGX) has a ThetaGrade House Rating of 49/100 (grade D), ranking #132 of 150 in Health Care. Its strongest pillars are balance sheet (99) and growth (81); its weakest is valuation (5). Data gap: 7 factors without usable data, so 52% of the method weight is covered. TTM revenue growth is 121.5% and operating margin -253.4%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change, Net debt / EBITDA, Interest coverage, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 52% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 81| Revenue growth YoY (TTM) (22.2%) | 121.5% | 95 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | 0.0% | 52 |
Profitability
weight 18.5% (→20.0%) · 5| Operating margin (20.0%) | -253.4% | 5 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 99| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (20.0%) | 50.82 | 99 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 8| FCF margin (6.7%) | -224.3% | 5 |
| FCF yield (6.7%) | -3.8% | 10 |
Valuation
weight 12.33% (→13.3%) · 5| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 62.64× | 5 |
Technicals (EOD)
| RSI(14) | 42.7 |
| EMA 9 / 21 | 22.74 / 23.21 |
| 200-day SMA | 21.65 |
| Volume vs 20d avg | 0.92× |
| 20-day return | -6.2% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Operating income: OperatingIncomeLoss · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like TNGX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is TNGX's House Rating?
- TNGX scores 49 out of 100 (grade D) as of 2026-10-16, ranking #132 of 150 Health Care stocks we cover.
- What do analysts say about TNGX?
- We do not have enough analyst-sentiment data to score this stock.
- When does TNGX report earnings next?
- We do not have a reliable estimate for TNGX's next earnings date (irregular SEC filing history); a rough window is 2026-08-16 to 2027-01-21. Check the company's investor-relations page.
- Is TNGX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology